Most people who take Ozempic for weight loss will need to stay on it indefinitely to keep the weight off. Stopping the medication typically leads to significant weight regain: on average, people regain about 60% of the weight they lost within one year of discontinuing treatment. That’s not a failure of willpower. It reflects how the body defends its fat stores through biological mechanisms that the drug suppresses but doesn’t permanently change.
It’s worth noting that Ozempic (semaglutide at lower doses) is FDA-approved only for type 2 diabetes, not for weight loss. The weight loss version of semaglutide is sold as Wegovy at a higher dose. Many doctors prescribe Ozempic off-label for weight management, but the distinction matters for insurance coverage and how long your plan will pay for it.
Why Weight Comes Back After Stopping
Your body treats excess fat as something worth protecting. When you lose weight, your brain ramps up hunger signals and slows calorie burn to push you back toward your previous weight. Semaglutide works by mimicking a natural gut hormone called GLP-1, which tells your brain you’re full and reduces appetite. As long as you’re taking the drug, those hunger signals stay quieter. The moment you stop, they come roaring back.
The STEP 4 clinical trial illustrated this clearly. Every participant started semaglutide for the first 20 weeks, then half continued the drug while the other half switched to a placebo. Over the next 48 weeks, those who stayed on semaglutide lost an additional 7.9% of their body weight. Those who switched to the placebo gained back 6.9%. Same people, same starting point, dramatically different outcomes based solely on whether they kept taking the medication.
Major medical organizations now classify obesity as a chronic disease, similar to high blood pressure or diabetes. The American Association of Clinical Endocrinology’s 2025 guidelines describe it as a condition that “necessitates long-term treatment and care.” The implication is straightforward: just as you wouldn’t stop blood pressure medication once your numbers improved, stopping obesity medication often reverses the benefit.
The Weight Loss Timeline
Weight loss on semaglutide doesn’t happen overnight, and it follows a fairly predictable arc. You’ll start on a low dose and gradually increase over several months to reduce nausea and other gastrointestinal side effects. Most people begin seeing meaningful weight loss within the first few months as the dose climbs.
Clinical trial data suggests that weight loss continues for roughly 60 weeks (about 14 months) before reaching a plateau. After that point, you’re in maintenance territory. Your weight stabilizes not because the drug stopped working, but because your body has reached a new equilibrium between the calories you’re eating and the calories you’re burning at your lower weight. The drug is still actively suppressing appetite and keeping weight stable at that lower level.
Can You Taper Off Successfully?
Some evidence suggests that a careful, gradual taper combined with strong lifestyle habits can help certain people maintain their weight loss after stopping. In one study, participants who were tapered off semaglutide over an average of about 10 weeks, while receiving support for lifestyle changes, maintained a stable body weight for the first 26 weeks after fully discontinuing the drug. That’s a more promising outcome than the abrupt-stop data from larger trials.
The key difference appears to be the combination of slow tapering and behavioral support. When you stop suddenly, appetite rebounds hard, and cravings become difficult to manage. A gradual reduction gives your body time to adjust and gives you time to build eating habits that can partially compensate for the loss of the drug’s appetite-suppressing effect. If you and your doctor decide to try discontinuing, expect the taper process to take roughly two to three months, and plan for intensive focus on diet and exercise habits during that window.
That said, 26 weeks of stable weight is not the same as permanent maintenance. Longer-term data on tapering strategies is still limited, and many people will eventually need to restart treatment.
Long-Term Safety Considerations
If you’re going to take a medication for years or potentially for life, safety matters. The news is mostly reassuring. Early concerns that GLP-1 drugs might increase the risk of pancreatitis or pancreatic cancer have been addressed by long-term clinical trials, which found no meaningful increase in risk.
One concern that has emerged involves a rare eye condition called non-arteritic anterior ischemic optic neuropathy, a type of sudden vision loss. A five-year study found that semaglutide use more than doubled the risk of this condition, though the baseline risk is very low to begin with. Gastrointestinal side effects like nausea, vomiting, and constipation are common early in treatment but tend to improve as your body adjusts.
A practical reality of long-term use: many people stop taking GLP-1 drugs within the first two years regardless of whether they planned to. Claims data shows that 68% of adults under 65 had discontinued within 24 months, with even higher rates among older adults. Cost, side effects, supply shortages, and insurance changes all play a role in those numbers.
What This Means for Your Decision
The honest answer is that semaglutide works best as a long-term or indefinite treatment. If you stop, you’ll likely regain most of the weight within a year or two. That doesn’t mean you have to commit to taking it forever before starting. Many people benefit from taking it for a year or more, reaching a lower weight, and then making a deliberate decision about next steps with their doctor.
If cost or access is a concern, a supervised taper with strong lifestyle support offers the best chance of holding onto some of your progress. But going in with realistic expectations matters. Think of the drug less like an antibiotic that cures an infection and more like glasses that correct your vision. It works while you’re using it. The underlying condition, a body that fiercely defends its highest weight, doesn’t resolve when treatment stops.